Kura Oncology, Inc. (KURA) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Kura Oncology, Inc. (KURA): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 31/100 — a percentile rank of Kura Oncology, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| Market cap | $947.4M |
| P / S | 12.3× |
| EV / EBITDA | -2.8× |
| Gross margin | 99.3% |
| Operating margin | -411.9% |
| Net margin | -384.3% |
| Return on equity | -612.8% |
| ROIC | 2646.9% |
| Revenue growth | -7.3% |
| Debt / equity | 0.2× |
| Dividend yield | 0.0% |
Is Kura Oncology, Inc. overvalued? P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Kura Oncology, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact